Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 425-220-8 | CAS number: 5945-33-5
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
An Ames test and a chromosome aberration in CHL test were performed on Fyrolflex BDP. Both in vitro studies were negative in the presence and absence of metabolic activation. Fyrolflex BDP did not induce any significant chromosomal damage in the CHL cells. Fyrolflex BDP was not mutagenic to E. coli or to S. typhimarium. The substance was also clearly negative in the L5178Y/TK+/- Mouse Lymphoma Mutagenesis Assay.
There is no evidence of genotoxic potential of Fyrolflex BDP. Robust summary for each study is attached in the endpoint of study record.
Short description of key information:
Reverse mutation assay Ämes test using Salmonella Typhimurium and Escherichia coli
Chromosome aberration test in CHL cells
In vitro mammalian cell gene mutation assay
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
The substance in not mutagenic.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
